{
  "id": 1570317,
  "title": "BofA initiates Definium Therapeutics stock with buy on psychedelic drug potential",
  "url": "https://urgent.news/2026/08/17/bofa-initiates-definium-therapeutics-stock-with-buy-on-psychedelic",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T21:40:48.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/bofa-initiates-definium-therapeutics-stock-with-buy-on-psychedelic-drug-potential-93CH-4864028"
  },
  "original_language": "en",
  "account": "BofA Securities has given Definium Therapeutics Inc (NASDAQ:DFTX) a \"buy\" rating and set a target price of $75.00 per share. The company's lead asset, DT120, is an LSD-based drug in pivotal studies for major depressive disorder and generalized anxiety disorder, with recent phase 3 studies showing promising results. BofA analysts believe DT120 could become a preferred option for patients with severe depression and anxiety if the positive trial outcomes are confirmed. The stock is currently trading at $45.28, presenting significant upside potential.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "BofA initiates Kanzhun stock coverage with neutral rating",
        "url": "https://urgent.news/2026/08/17/bofa-initiates-kanzhun-stock-coverage-with-neutral-rating",
        "published": "2026-08-17T21:40:53.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}